Founder, Chairman and CEO - Phase 3 CNS Gene Therapy at LYSOGENE
Karen Aiach is a(n) Founder, Chairman and CEO - Phase 3 CNS Gene Therapy working at LYSOGENE.
Get Karen Aiach's email for freeName | Position | Contacts | ||
---|---|---|---|---|
RL | Ralph Laufer | Chief Scientific OfficerLYSOGENE | @lys….com | Get contact |
SA | Stephane Aulnois | Chief Financial OfficerLYSOGENE | @lys….com | Get contact |
JL | Julie Labit | Executive Assistant CEO & FounderLYSOGENE | @lys….com | Get contact |
LG | Laura Giersch | Manager of Technical OperationsLYSOGENE | @lys….com | Get contact |
SA | Sarah Ankri | Finance Director / Directrice financièreLYSOGENE | @lys….com | Get contact |
SP | Samantha Parker | Chief Patient Affairs/Health Policies OfficerLYSOGENE | @lys….com | Get contact |
KA | Karen Aiach | CEOLYSOGENE | @lys….com | Get contact |
MP | Mark Plavsic | Chief Technology OfficerLYSOGENE | @lys….com | Get contact |
SO | Sophie Olivier | Chief Medical OfficerLYSOGENE | @lys….com | Get contact |
AM | Alice Meur | Clinical Project ManagerLYSOGENE | @lys….com | Get contact |